Septerna, Inc. (SEPN)
| Market Cap | 2.03B +135.3% |
| Revenue (ttm) | 96.27M +336.7% |
| Net Income | -59.00M |
| EPS | -1.31 |
| Shares Out | 47.55M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 337,793 |
| Open | 41.27 |
| Previous Close | 41.86 |
| Day's Range | 40.60 - 42.88 |
| 52-Week Range | 18.64 - 53.34 |
| Beta | 2.20 |
| Analysts | Strong Buy |
| Price Target | 59.22 (+39.01%) |
| Earnings Date | Nov 9, 2026 |
About SEPN
Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. It develops PTH1R Program, oral small molecule Parathyroid Hormone 1 Receptor agonists for the treatment of hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 negative allosteric modulator (NAM) for chronic spontaneous urticaria and other mast cell diseases; and TSHR Program, an oral small molecule TSHR NAM f... [Read more]
Financial Performance
In 2025, Septerna's revenue was $45.95 million, an increase of 4174.51% compared to the previous year's $1.08 million. Losses were -$48.88 million, -31.92% less than in 2024.
Financial StatementsAnalyst Summary
According to 10 analysts, the average rating for SEPN stock is "Strong Buy." The 12-month stock price target is $59.22, which is an increase of 39.01% from the latest price.
News
Septerna Transcript: Stifel 2026 Healthcare Conference 2026
SEP-479 phase I data are expected in Q1 next year, with phase II planned afterward; SEP-204 is advancing toward phase I after encouraging preclinical Graves’ and TED findings. Cash of $565 million at Q3-end supports runway into at least mid-2029.
Septerna price target raised to $60 from $49 at Stifel
Stifel raised the firm’s price target on Septerna (SEPN) to $60 from $49 and keeps a Buy rating on the shares.
Septerna Transcript: 3rd Annual Guggenheim Healthcare Innovation Conference
SEP-479 Phase I results are expected in Q1 2027, with patient Phase II planned for H2 2027. SEP-204 is targeted to enter the clinic in Q1 2027 for Graves’ disease and thyroid eye disease; cash runway extends through mid-2029.
Septerna Highlights Business Progress and Reports Third Quarter 2026 Financial Results
Phase 1 Clinical Trial for PTH1R Agonist SEP-479 Ongoing; SAD / MAD Data Expected in Q1 2027 Plans to Initiate Phase 1 Clinical Trial of Newly Selected Oral TSHR NAM Development Candidate SEP-204 in Q...
Septerna Earnings release: Q3 2026
Septerna released its Q3 2026 earnings on November 9, 2026, summarizing the period's financial results.
Septerna Quarterly report: Q3 2026
Septerna has published its Q3 2026 quarterly earnings report on November 9, 2026.
Septerna price target raised to $65 from $51 at Guggenheim
Guggenheim analyst Seamus Fernandez raised the firm’s price target on Septerna (SEPN) to $65 from $51 and keeps a Buy rating on the shares, citing a belief that the company…
Septerna Announces Selection of SEP-204 as Development Candidate for Graves' Disease and TED and Reports Preclinical Data at the 2026 American Thyroid Association Annual Meeting
Potent, selective TSHR NAM with pre-clinical activity demonstrated across biochemical, thyroid and ocular endpoints Favorable PK profile anticipated to support once-daily oral dosing in humans Phase 1...
Septerna price target raised to $61 from $50 at Wells Fargo
Wells Fargo raised the firm’s price target on Septerna (SEPN) to $61 from $50 and keeps an Overweight rating on the shares following a SEP-479 deep dive. The firm’s cross-program,…
Septerna to Participate in Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug disc...
3 Small-Cap Stocks Analysts Expect to Rally over 35%
Small-cap stocks often go unnoticed, but a few are grabbing Wall Street’s attention. Analysts are highlighting Septerna, Inc. ($SEPN), Progress Software ($PRGS), and AngioDynamics ($ANGO) as companies...
Septerna, Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), today announced that the Company granted a non-qualified stock option to purchase up to 275,000 shares of...
Septerna Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference
The company is advancing a GPCR-focused pipeline with SEP-479 in phase I for hypoparathyroidism, supported by strong financials and a Novo Nordisk partnership. Key programs target endocrine and metabolic diseases, with strategic plans for global commercialization and innovative trial designs.
Septerna Transcript: Wells Fargo 21st Annual Healthcare Conference
The company is advancing an oral PTH receptor agonist for hypoparathyroidism, with full phase I data expected in Q1 next year, and is expanding its pipeline with programs in Graves' disease, osteoporosis, and mast cell diseases. Regulatory changes and platform innovations are enabling faster, more efficient development.
Septerna Appoints Industry Veteran Rajiv Patni, M.D., as Chief Medical Officer
SOUTH SAN FRANCISCO, Calif., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug disc...
Septerna price target raised to $48 from $38 at JPMorgan
JPMorgan raised the firm’s price target on Septerna (SEPN) to $48 from $38 and keeps an Overweight rating on the shares.
Septerna price target raised to $60 from $40 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Septerna (SEPN) to $60 from $40 and keeps a Buy rating on the shares post the Q2 report. The firm says SEP-479…
Septerna price target raised to $62 from $43 at Jones
Jones analyst Catherine Novack raised the firm’s price target on Septerna (SEPN) to $62 from $43 and keeps a Buy rating on the shares. The company reported Q2 earnings and…
Septerna price target raised to $49 from $45 at Raymond James
Raymond James raised the firm’s price target on Septerna (SEPN) to $49 from $45 and keeps a Strong Buy rating on the shares. The firm updated its model post the…
Septerna price target raised to $51 from $45 at Guggenheim
Guggenheim raised the firm’s price target on Septerna (SEPN) to $51 from $45 and keeps a Buy rating on the shares. The firm is increasing its view of the odds…
Septerna reports Q2 EPS (29c), consensus (49c)
Reports Q2 revenue $26.75M, consensus $19.22M. “We continue to make meaningful progress across our portfolio as we execute on our strategy to develop differentiated oral medicines targeting GPCRs,” sa...
Septerna Quarterly report: Q2 2026
Septerna has published its Q2 2026 quarterly earnings report on August 10, 2026.
Septerna Earnings release: Q2 2026
Septerna released its Q2 2026 earnings on August 10, 2026, summarizing the period's financial results.
Septerna Slides: Investor presentation
Septerna has posted slides in relation to its latest quarterly earnings report, which was published on August 10, 2026.